Cell Death and Differentiation · 2023 · 64 citations · 42 references
Life SciencesGeneticsOncologyGene ExpressionMetastasisMolecular OncologyCancer TranscriptomicsNoncoding Rna BiologyNoncoding Rna TranscriptomicsOncogenic ProliferationTranscription Factor OncogenesTumor Suppressor GenesLong Non-coding Ribonucleic AcidsLong Noncoding Rna RegulationMesenchymal TransitionMyc In Lung CancerNoncoding Rna Expression ProfilingOncogenic Driver MutationsOncogenic Noncoding RnaTumor Metastasis Biology
Abstract Lung cancer is the leading cause of cancer-related deaths worldwide. KRAS is the main oncogenic driver in lung cancer that can be activated by gene mutation or amplification, but whether long non-coding RNAs (lncRNAs) regulate its activation remains unknown. Through gain and loss of function approaches, we identified that lncRNA HIF1A-As2 , a KRAS-induced lncRNA, is required for cell proliferation, epithelial-mesenchymal transition (EMT) and tumor propagation in non-small cell lung cancer (NSCLC) in vitro and in vivo. Integrative analysis of HIF1A-As2 transcriptomic profiling reveals that HIF1A-As2 modulates gene expression in trans, particularly regulating transcriptional factor genes including MYC. Mechanistically, HIF1A-As2 epigenetically activates MYC by recruiting DHX9 on MYC promoter, consequently stimulating the transcription of MYC and its target genes. In addition, KRAS promotes HIF1A-As2 expression via the induction of MYC, suggesting HIF1A-As2 and MYC form a double-regulatory loop to strengthen cell proliferation and tumor metastasis in lung cancer. Inhibition of HIF1A-As2 by LNA GapmeR antisense oligonucleotides (ASO) significantly improves sensitization to 10058-F4 (a MYC-specific inhibitor) and cisplatin treatment in PDX and KRAS LSLG12D -driven lung tumors, respectively.
42
MEME SUITE: tools for motif discovery and searching
Timothy L. Bailey, Mikael Bodén, Fabian A. Buske et al. · Nucleic Acids Research · 2009 · 11.5K citations · Full text